B7-H4-targeting antibody-drug conjugate delivering a topoisomerase I inhibitor payload to induce DNA damage and tumor cell death.
Humanized IgG1 anti-B7-H4 antibody linked via a protease-cleavable linker to a topoisomerase I inhibitor. After binding B7-H4 on tumor cells and internalization, the payload inhibits TOP1 by stabilizing TOP1-DNA cleavage complexes, blocking DNA re-ligation and causing DNA strand breaks, cell-cycle arrest, and apoptosis in B7-H4-expressing tumor cells.
YES
DIRECT
ADC binds B7-H4 on target cells, is internalized, and releases a topoisomerase I inhibitor that stabilizes TOP1-DNA cleavage complexes, causing DNA breaks, cell-cycle arrest, and apoptosis.
B7-H4-targeting antibody-drug conjugate delivering a topoisomerase I inhibitor payload to induce DNA damage and tumor cell death.
Humanized IgG1 anti-B7-H4 antibody linked via a protease-cleavable linker to a topoisomerase I inhibitor. After binding B7-H4 on tumor cells and internalization, the payload inhibits TOP1 by stabilizing TOP1-DNA cleavage complexes, blocking DNA re-ligation and causing DNA strand breaks, cell-cycle arrest, and apoptosis in B7-H4-expressing tumor cells.
NO
INDIRECT
The ADC binds B7-H4 on tumor cells, is internalized, and releases a TOP1 inhibitor that causes DNA damage and apoptosis. Killing depends on B7-H4 targeting, not merely on Topoisomerase I expression.
A targeted biologic HER2 dual antibody–drug conjugate (ADC) given IV every 3 weeks; two anti‑HER2 antibodies bind ERBB2 on tumor cells, drive receptor-mediated internalization, and release an intracellular cytotoxic payload to induce tumor cell death; binding may also inhibit HER2 signaling.
HER2-directed antibody–drug conjugate in which humanized anti-HER2 antibodies bind ERBB2 on tumor cells, trigger receptor-mediated internalization, and enzymatic cleavage of a linker to release a topoisomerase I inhibitor payload. The released payload inhibits Topo I, blocking DNA replication and causing cell-cycle arrest and apoptosis; antibody binding may also hinder HER2 signaling.
YES
DIRECT
The ADC binds HER2 on target cells, is internalized, and enzymatic linker cleavage releases a topoisomerase I inhibitor payload that blocks DNA replication, causing DNA damage, cell-cycle arrest, and apoptosis (with possible additional HER2 signaling inhibition).
Donor-derived antigen-specific CD4+ and CD8+ T lymphocytes selected by IFN-γ capture after brief stimulation with CMV, EBV, and adenovirus peptides; infused as adoptive cellular therapy to restore antiviral immunity in allo-HSCT recipients.
Donor-derived CD4+ and CD8+ T lymphocytes are briefly stimulated with CMV, EBV, and adenovirus peptides and IFN-γ–secreting cells are magnetically captured, enriching for virus-specific TCR specificities. After infusion, these unengineered T cells recognize HLA-presented viral epitopes via their native TCRs, secrete Th1 cytokines (e.g., IFN-γ), and kill infected cells through perforin/granzyme-mediated cytotoxicity, expanding in vivo to restore antiviral immunity in allo-HSCT recipients.
YES
DIRECT
Virus-specific T cells recognize EBV peptide–HLA complexes via their native TCR and directly kill infected cells through perforin/granzyme-mediated cytotoxicity (and Fas–FasL).
A targeted biologic HER2 dual antibody–drug conjugate (ADC) given IV every 3 weeks; two anti‑HER2 antibodies bind ERBB2 on tumor cells, drive receptor-mediated internalization, and release an intracellular cytotoxic payload to induce tumor cell death; binding may also inhibit HER2 signaling.
HER2-directed antibody–drug conjugate in which humanized anti-HER2 antibodies bind ERBB2 on tumor cells, trigger receptor-mediated internalization, and enzymatic cleavage of a linker to release a topoisomerase I inhibitor payload. The released payload inhibits Topo I, blocking DNA replication and causing cell-cycle arrest and apoptosis; antibody binding may also hinder HER2 signaling.
NO
INDIRECT
TQB2102 targets HER2, is internalized, and releases a Topo I–inhibiting payload that blocks DNA replication and induces apoptosis. Killing depends on HER2 binding; Topo I is the intracellular enzymatic target, not the cell-selective antigen.